Where to buy sofosbuvir and velpatasvir (Epclusa)

Sofosbuvir (Epclusa) is an oral, fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an NS5A replication complex inhibitor. Sofosbuvir is currently approved in the United States for the treatment of HCV genotypes 1-6. Velpatasvir (formerly GS-5816) is a novel NS5A inhibitor with potent in vitro anti-HCV activity at picomolar levels against all genotypes. The combination of sofosbuvir and velpatasvir is the first once-daily, single-tablet regimen with pan-genotypic activity.

The fixed-dose combination sofosbuvir and velpatasvir (400 mg/100 mg) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C genotypes 1 to 6 in the following patient populations, including patients without cirrhosis and patients with compensated cirrhosis (Child-Pugh A), this combination can be used for 12 weeks of treatment, and patients with decompensated cirrhosis(Child-Pugh B and C) can be treated with this combination plus ribavirin treatment12 weeks for 12 weeks.

The original drug of sofosbuvir and velpatasvir has been marketed in China and has entered the scope of Class B medical insurance. The domestic trade name is Bintongsha. The specification (400mg+100mg)*28 tablets is priced at about RMB 4,000 per box. Domestic pharmacies or hospitals may sell this drug. The original drug of sofosbuvir and velpatasvir has also been launched overseas. There are also generic drugs of sofosbuvir and velpatasvir produced in other countries. The price of the specification (400mg+100mg) *28 tablets per box produced by Everest Pharmaceutical Factory in Bangladesh is around RMB 850 (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the original drugs at home and abroad. For more drug information and prices, please consult the medical consultant of Yaode.